Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib.

× No keyword cloud information.

8 in total

1. Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia.

Authors: O Kosmider; R Itzykson; V Chesnais; T Lasho; R Laborde; R Knudson; A Gauthier; J Merlevede; L Ades; M Morabito; M Fontenay; A Tefferi; N Droin; E Solary
Journal: Leukemia Date: 2013-06-18 Impact factor: 11.528

2. Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia.

Authors: Renée Beekman; Marijke G Valkhof; Mathijs A Sanders; Paulette M H van Strien; Jurgen R Haanstra; Lianne Broeders; Wendy M Geertsma-Kleinekoort; Anjo J P Veerman; Peter J M Valk; Roel G Verhaak; Bob Löwenberg; Ivo P Touw
Journal: Blood Date: 2012-02-27 Impact factor: 22.113

3. A truncation mutant of Csf3r cooperates with PML-RARα to induce acute myeloid leukemia in mice.

Authors: Ghada Kunter; Jill R Woloszynek; Daniel C Link
Journal: Exp Hematol Date: 2011-09-10 Impact factor: 3.084

4. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.

Authors: A Pardanani; T L Lasho; R R Laborde; M Elliott; C A Hanson; R A Knudson; R P Ketterling; J E Maxson; J W Tyner; A Tefferi
Journal: Leukemia Date: 2013-04-22 Impact factor: 11.528

5. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.

Authors: Angela G Fleischman; Julia E Maxson; Samuel B Luty; Anupriya Agarwal; Lacey R Royer; Melissa L Abel; Jason D MacManiman; Marc M Loriaux; Brian J Druker; Jeffrey W Tyner
Journal: Blood Date: 2013-09-30 Impact factor: 22.113

6. In vivo expansion of cells expressing acquired CSF3R mutations in patients with severe congenital neutropenia.

Authors: Manuela Germeshausen; Karl Welte; Matthias Ballmaier
Journal: Blood Date: 2008-11-19 Impact factor: 22.113

7. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.

Authors: Julia E Maxson; Jason Gotlib; Daniel A Pollyea; Angela G Fleischman; Anupriya Agarwal; Christopher A Eide; Daniel Bottomly; Beth Wilmot; Shannon K McWeeney; Cristina E Tognon; J Blake Pond; Robert H Collins; Basem Goueli; Stephen T Oh; Michael W Deininger; Bill H Chang; Marc M Loriaux; Brian J Druker; Jeffrey W Tyner
Journal: N Engl J Med Date: 2013-05-09 Impact factor: 91.245

8. An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia.

Authors: Isabelle Plo; Yanyan Zhang; Jean-Pierre Le Couédic; Mayuka Nakatake; Jean-Michel Boulet; Miki Itaya; Steven O Smith; Najet Debili; Stefan N Constantinescu; William Vainchenker; Fawzia Louache; Stéphane de Botton
Journal: J Exp Med Date: 2009-07-20 Impact factor: 14.307

8 in total

23 in total

1. Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia.

Authors: Arief S Gunawan; Donal P McLornan; Bridget Wilkins; Katherine Waghorn; Yvette Hoade; Nicholas C P Cross; Claire N Harrison
Journal: Haematologica Date: 2017-03-16 Impact factor: 9.941

10. Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis.

Authors: S E Langabeer; K Haslam; J Kelly; J Quinn; R Morrell; E Conneally
Journal: Clin Transl Oncol Date: 2017-07-31 Impact factor: 3.405

Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib.

1. Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia.

2. Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia.

3. A truncation mutant of Csf3r cooperates with PML-RARα to induce acute myeloid leukemia in mice.

4. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.

5. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.

6. In vivo expansion of cells expressing acquired CSF3R mutations in patients with severe congenital neutropenia.

7. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.

8. An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia.

1. Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia.

Review 2. Somatic SETBP1 mutations in myeloid neoplasms.

3. B-lymphoblastic leukemia arising in a patient with chronic neutrophilic leukemia.

4. Chronic neutrophilic leukemia with overexpression of EVI-1, and concurrent CSF3R and SETBP1 mutations: A case report.

5. Chronic neutrophilic leukemia.

Review 6. Genomics of chronic neutrophilic leukemia.

Review 7. Turning the tide in myelodysplastic/myeloproliferative neoplasms.

8. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.

Review 9. Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.

10. Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis.